Gonococcal and Chlamydial Infections
Posted October 2007 — Currently Under Revision
Neisseria gonorrhoeae and Chlamydia trachomatis are the principal bacterial pathogens associated with sexually transmitted pharyngitis, urethritis, cervicitis, proctitis, epididymitis, and pelvic inflammatory disease.
Gonorrhea and chlamydia are common in the United States, and there are a number of reports documenting high prevalence and incidence of infection in the HIV-infected population. Several studies have shown that infection with N gonorrhoeae and/or C trachomatis may increase both the risk of transmission and acquisition of HIV.4-6
II. SCREENING PATIENTS FOR GONOCOCCAL AND CHLAMYDIAL INFECTIONS
Clinicians should screen sexually active HIV-infected women under the age of 25 for gonorrhea and chlamydia at baseline and at least annually. Clinicians should screen all sites of possible exposure, including the cervix, rectum, and pharynx. Culture or nucleic acid tests (NAT) should be used to screen for gonorrhea. Immunofluorescence or DNA amplification should be used for chlamydia.
Clinicians should screen women 25 years of age or older for gonorrhea and chlamydia at baseline and at least annually if they have or have had a recent sexually transmitted infection, have multiple sexual partners, have had a new sexual partner, or have a sexual partner with symptoms of an STI.
Clinicians should screen all HIV-infected men with ongoing high-risk sexual behaviors for gonorrhea and chlamydia at baseline and at least annually. Clinicians should screen all sites of possible exposure, including the urethra, rectum, and pharynx.
All sites of possible exposure should be screened.7 Presently, nucleic acid tests (NATs) are not approved for use on pharyngeal or rectal specimens, although NATs are more sensitive than culture. When available, culture is preferred because it is effective for all potential sites of infection and permits testing for drug susceptibility. More frequent screening for gonorrhea and chlamydia may be indicated for patients with continued high-risk sexual behavior. Table 1 provides information regarding annual screening of patients for gonococcal and chlamydial infection.
III. DIAGNOSIS AND TREATMENT
Clinicians managing HIV-infected patients with gonococcal and/or chlamydial infections should follow the same diagnosis and treatment recommendations as those for non-HIV-infected patients.
Clinicians should not use fluoroquinolones to treat proven or suspected gonococcal infections.
Chlamydial infections should be treated with azithromycin 1 g single dose or doxycycline 100 mg bid for 7 days. Ceftriaxone 250 mg IM plus a single 1-g dose of azithromycin is the preferred treatment for uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx.
Clinicians must report all suspected or confirmed gonococcal and C trachomatis infections to the local health department of the area where the patient resides according to NYS requirements (also see reportable communicable diseases).
The incidence of concomitant gonorrhea and chlamydia is high among HIV-infected patients who have a confirmed diagnosis of either infection. However, with the exception of studies of women hospitalized with pelvic inflammatory disease, there have been no formal studies evaluating differences in clinical presentation, diagnosis, or response to treatment of gonococcal or chlamydial infection in HIV-infected patients. In addition, there have been no reports of atypical presentations or failure of standard therapy in HIV-infected patients. Diagnostic tests (see Table 2) and treatment recommendations are identical to those in non-HIV-infected patients.8
Chlamydial infections should be treated with azithromycin 1 g single dose or doxycycline 100 mg bid for 7 days. Ceftriaxone 250 mg IM is the preferred treatment for uncomplicated gonococcal infections of the cervix, urethra, rectum, and pharynx.
Cephalosporin-resistant N. gonorrhoeae has been reported outside of the United States.1,2 However, isolates of N. gonorrhoeae recently showed reduced susceptibility to cephalosporins in New York City.3 To prevent further emergence of cephalosporin resistance, the CDC and NYSDOH are now recommending ceftriaxone 250 mg plus a single 1-g dose of azithromycin as the most effective treatment for uncomplicated gonorrhea. Fluoroquinolones should no longer be used to treat proven or suspected gonococcal infections because of the significant increases in quinolone-resistant N gonorrhoeae (QRNG) in the United States.9 For example, New York City Department of Health and Mental Hygiene STI clinics have reported high incidences of QRNG (14.9% in 2007; 15.5% in 2008).10 Clinicians must report all gonococcal infections, and C trachomatis infections, to the local public health department of the area where the patient resides. More information regarding communicable disease reporting requirements is available at: www.health.ny.gov/professionals/diseases/reporting/communicable
Diagnosis and Treatment of Patients With Penicillin Allergy
Clinicians should treat patients with uncomplicated gonococcal infection who have penicillin allergy, and for whom penicillin desensitization is not possible, with 2 g of azithromycin.
For patients with a history of severe penicillin allergy, in whom cephalosporins would also be contraindicated, there is no consensus on management. Therefore, the recommendations in this section are based on expert opinion.
Penicillin desensitization is the ideal approach for patients with severe penicillin allergy. However, this is not practical in many settings, including emergency rooms. Alternative practices include treatment with 2 g of azithromycin for uncomplicated gonococcal infection in patients with a penicillin allergy; however, increasing resistance is of concern if use is widespread. In patients with penicillin allergy, culture for N gonorrhoeae, instead of NAT testing, at the patient’s initial visit may be preferred because sensitivity testing could then be performed. If results show that the patient’s isolate is resistant to azithromycin, then the patient should be asked to return for a change in treatment.
Sensitivity testing can be used to determine whether a gonococcal isolate is sensitive to fluoroquinolones. A fluoroquinolone is an alternative for initial treatment, as long as:
- Culture and sensitivity testing are performed and
- Patient contact information is available for follow-up and
- Empiric treatment of chlamydia is given as standard of care
Spectinomycin is a theoretical treatment option for these patients. Although spectinomycin is not currently manufactured or sold in the United States, the CDC and the Food and Drug Administration have reported efforts to resume its availability.11 Spectinomycin is not considered adequate for the treatment of pharyngeal gonococcal infections.9
IV. TREATMENT FOLLOW-UP
Patients treated for confirmed gonorrhea should receive a follow-up physical examination and a test of cure from gonococcal-infected sites at 2 weeks post-treatment if using culture or at 4 weeks post-treatment if using NAT, regardless of whether or not symptoms have resolved. If the post-treatment NAT is positive, a culture should be performed to assess for resistance.
Clinicians should retest patients treated for confirmed gonorrhea or chlamydial infection at least 3 months after treatment completion for evidence of reinfection.
The NYSDOH recommends that after the completion of treatment for uncomplicated gonorrhea, patients should receive a follow-up physical examination and a test of cure (TOC) from gonococcal-infected sites as described above. In addition, patients treated for gonorrhea should be retested at 3 months for evidence of reinfection. Isolates from treatment failures should be tested for antibiotic resistance. For additional information, see the NYSDOH Bureau of Sexually Transmitted Disease Control Health Alert: Treatment for Fluoroquinolone-resistant (QRNG) Gonorrhea.12
The CDC guidelines do not recommend a TOC for patients who have been treated with recommended or alternative regimens for uncomplicated gonorrhea. For additional information, see the CDC’s Sexually Transmitted Diseases Treatment Guidelines.8
Of note, treatment failures may occur for a variety of reasons:
- Reinfection rates are high: a patient may be reinfected by a new partner or an untreated current partner.
- The treatment of the patient and partner may not have overlapped, thereby allowing the infection to pass back and forth between partners.
- Treatment may fail to eradicate organisms from the rectum or pharynx of the patient or his/her partner. For patients with persistent gonococcal symptoms, additional testing should include C trachomatis culture when possible and examination for Trichomonas vaginalis.
V. MANAGEMENT OF PARTNERS
Clinicians should consider both HIV and STI exposures to partners when HIV-infected patients present with a new STI. Clinicians should also assess for the presence of other STIs (see Management of STIs in HIV-Infected Patients). (AIII)
A. Management of HIV Exposure in Partners
Updated March 2012
When HIV-infected patients present with a new STI, clinicians should offer assistance with notifying partners of both the potential HIV and STI exposures or should refer patients to other sources for partner notification assistance ( Partner Services in New York State or CNAP in New York City). Partners without confirmed HIV infection should undergo HIV testing at baseline, 1, 3, and 6 months. Confirmatory testing according to New York State regulations must be performed to confirm HIV diagnoses.
Clinicians must report confirmed cases of HIV according to New York State Public Health Law (for more information about required reporting, see www.health.ny.gov/diseases/aids/regulations/partner_services/index.htm).
Clinicians should educate patients with non-HIV-infected partners or partners of unknown HIV status to be vigilant for any post-exposure acute HIV symptoms in their partners, such as febrile illness accompanied by rash, lymphadenopathy, myalgias, and/or sore throat (see Diagnosis and Management of Acute HIV Infection). (AIII)
Partners who present within 36 hours of an HIV exposure should be evaluated as soon as possible for initiation of post-exposure prophylaxis therapy (see HIV Prophylaxis Following Non-Occupational Exposure). (AII)
Presentation of a new STI in HIV-infected patients suggests exposure of both HIV and the STI to their partners. In this case, offering HIV non-occupational post-exposure prophylaxis (nPEP) to partners is usually not an option because the period prior to STI symptom onset is usually longer than the 36-hour window for initiating HIV nPEP. Therefore, sequential HIV testing of partners without confirmed HIV infection should be performed for early identification of potential HIV acquisition. However, if a patient with an HIV exposure does present within 36 hours, evaluation for nPEP should occur (see HIV Prophylaxis Following Non-Occupational Exposure).
B. Management of Gonococcal and/or Chlamydial Exposure
Sex partners of patients with gonococcal and/or chlamydial infections should be treated or referred for treatment if the partner was exposed within 60 days prior to symptom onset.
To prevent serial reinfection and curtail further transmission, sex partners of patients with gonococcal and/or chlamydial infections should be treated or referred for treatment if the partner was exposed within 60 days prior to symptom onset. No data are available regarding the optimal contact interval.
Considerations of HIV exposure in the partner need to be thoroughly examined before clinicians consider prescribing expedited partner therapy (EPT). For information regarding EPT in New York State, see www.nyhealth.gov/publications/3847 (for New York State providers) and www.nyc.gov/health/ept (for New York City providers). Additional information is also available from the CDC at http://cdc.gov/std/ept
1. Centers for Disease Control and Prevention. Cephalosporin Susceptibility Among Neisseria gonorrhoeae Isolates—United States, 2000–2010. MMWR Morbid Mortal Wkly Rep 2011;60:873-877. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6026a2.htm
2. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012;366:485-487. [PubMed]
3. New York City Department of Health and Mental Hygiene. 2012 Alert#1: Neisseria gonorrhoeae Isolates with Reduced Susceptibility to Cephalosporins. New York; 2012. Available at: http://www.nyc.gov/html/doh/downloads/pdf/cd/2012/12md01.pdf
4. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997;349:1868-1873. [PubMed]
5. Laga M, Manoka A, Kivuvu M, et al Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: Results from a cohort study. AIDS 1993;7:95-102. [PubMed]
6. Levine WC, Pope V, Bhoomkar A, et al. Increase in endocervical CD4 lymphocytes among women with non-ulcerative sexually transmitted diseases. J Infect Dis 1998;177:167-174. [PubMed]
7. Phipps W, Stanley H, Kohn R, et al. Syphilis, chlamydia, and gonorrhea screening in HIV-infected patients in primary care, San Francisco, California, 2003. AIDS Patient Care STDs 2005;19:495-498. [PubMed]
8. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2010. Available at: http://cdc.gov/std/treatment
9. Centers for Disease Control and Prevention. Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morbid Mortal Wkly Rep 2007;56:332-336. Available at: http://cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm
10. Centers for Disease Control and Prevention. 2008 Sexually Transmitted Diseases Surveillance: Gonorrhea. Atlanta, GA. Available at: http://www.cdc.gov/std/stats08/gonorrhea.htm
11. Centers for Disease Control and Prevention. Notice to readers: Discontinuation of spectinomycin. MMWR Morb Mortal Wkly Rep 2006;55;370. Available at: http://cdc.gov/mmwr/preview/mmwrhtml/mm5513a5.htm
12. NYSDOH Bureau of Sexually Transmitted Disease Control. Health alert: Treatment for fluoroquinolone-resistant (QRNG) gonorrhea. Available at: http://www.health.state.ny.us/diseases/communicable/std/docs/fluoroquinolones_advisory.pdf